Journal article
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.
- Abstract:
-
OBJECTIVES: To evaluate the efficacy and safety of intravenous ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, active rheumatoid arthritis (RA) patients despite methotrexate treatment. METHODS: In this double-blind, placebo-controlled, phase III study, active RA patients on stable methotrexate were randomly assigned to one course of two infusions of ofatumumab 700 mg (n=130) or placebo (n=130), 2 weeks apart. The primary endpoint was the ACR20 response at week 2...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Annals of the rheumatic diseases
- Volume:
- 70
- Issue:
- 12
- Pages:
- 2119-2125
- Publication date:
- 2011-12-01
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
- Source identifiers:
-
329928
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:329928
- UUID:
-
uuid:ba440a1a-4d8c-4198-8db4-01c182c98a37
- Local pid:
- pubs:329928
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2011
If you are the owner of this record, you can report an update to it here: Report update to this record